Randomized Controlled Trial of Argatroban With Tissue Plasminogen Activator (tPA) for Acute Stroke

Stopped The study was halted prematurely at 90 of 105 planned patients due to the beneficial results of embolectomy clinical trials.

Conditions

• Ischemic Stroke

Interventions

• DRUG: Low Dose Argatroban
• DRUG: High Dose Argatroban
• DRUG: rt-PA (alteplase)

Sponsor

Andrew D. Barreto, MD

Collaborators

• [object Object]